节拍式化疗在血液系统恶性肿瘤中的应用概述  

Overview of the application of metronomic chemotherapy in hematological malignancies

作　　者：李鑫淼 马邦云 庞洁[1] 孙雪梅[1] Li Xinmiao;Ma Bangyun;Pang Jie;Sun Xuemei(Department of Hematology,Affiliated Hospital of Nanjing University of Chinese Medicine,Nanjing 210029,China)

机构地区：[1]南京中医药大学附属医院血液科,南京210029

出　　处：《中国医药》2025年第3期467-471,共5页China Medicine

基　　金：国家自然科学基金(82305338);江苏省中医院高峰学术人才培养项目(Y2021rc05);南京中医药大学自然科学基金(XZR2021017)。

摘　　要：节拍式化疗(MCT)是一种以小剂量、高频率给药方式为特点的治疗手段,具有低毒性、药效持续时间长、依从性高、价格低廉等优势,临床上常作为血液系统恶性肿瘤晚期患者的挽救性措施,有一定临床实用性。本文探讨了MCT的作用机制,即抑制肿瘤干细胞、抗肿瘤血管生成及刺激免疫3个方面,并总结了目前MCT在多发性骨髓瘤、急性髓系白血病及淋巴瘤中的相关研究成果,阐述MCT的现状并指出不足之处,为其在血液系统恶性肿瘤中的临床应用提供参考,并为MCT研究的深入开展提供借鉴。Metronomic chemotherapy(MCT)is a treatment characterized by low-dose and high-frequency administration,which has the advantages of low toxicity,long duration of drug effect,high compliance,and low cost.It is often used as a salvage measure for patients with advanced hematological malignancies and has certain clinical practicability.In this review,we discuss the mechanisms of MCT,including inhibition of tumor stem cells,anti-angiogenesis and immune stimulation,and summarize the current research results of MCT in multiple myeloma,acute myeloid leukemia and lymphoma.We also elaborate the current status of MCT and point out the shortcomings,so as to provide reference for its clinical application in hematological malignancies.It also provides a reference for the in-depth development of MCT research.

关 键 词：血液系统恶性肿瘤 节拍式化疗 机制 多发性骨髓瘤 急性髓系白血病 淋巴瘤 

分 类 号：R733[医药卫生—肿瘤]